Company intelligence / Profile preview

Edinburgh Molecular Imaging

Edinburgh, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

The company has developed optical imaging agents that have shown success in real-time cancer margin assessment in breast, thyroid, and penile cancer. Their first agent EMI-137 is approaching commercialization and is preparing for Phase III clinical studies. They have also recently administered their first theragnostic agents to humans.

Therapeutic areas: Infectious DiseasesImmunologyPulmonologyOncology
Modalities: Small moleculespeptidesfluorescent imaging reagentsradiopharmaceuticals
Industry: Biotech

Drug pipeline

1 asset

emi-137

Partnerships

Life Molecular Imaging (LMI)

Beyond the preview

Go deeper on Edinburgh Molecular Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edinburgh Molecular Imaging.

Explore the full profile